KraneShares MSCI All China Health Care Index ETF(KURE · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$15.20
- 52-Week Range
- $14.38 – $21.88
- YTD
- -12.60%
- IV Rank (30D)
- 39.58
- Straddle Price
- $1.75
Info
KraneShares MSCI All China Health Care Index ETF (KURE) ETF
- Exchange
- ARCX
- Inception
- 2018-01-31
- Has Options
- Yes
ETF Profile
holdings as of 2026-03-31
Holdings
58
AUM
$77.2M
Provider
Unknown
Inception
2018-01-31
Exchange
ARCX
Data As Of
2026-03-31
Expense Ratio
—
Dividend Yield
4.71%
Distribution
Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-22 | 2025-12-23 | $0.7147 | CD |
| 2024-12-17 | 2024-12-18 | $0.1836 | CD |
| 2023-12-18 | 2023-12-20 | $0.1128 | CD |
| 2022-12-28 | 2022-12-30 | $0.0104 | CD |
| 2021-12-29 | 2021-12-31 | $4.0535 | CD |
Asset Allocation
Top Holdings
top 50 of 58 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| BEIGF | BeOne Medicines AG | 8.37% | Equity (common) | HK |
| — | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 8.25% | Equity (common) | CN |
| — | INNOVENT BIOLOGICS, INC. | 7.23% | Equity (common) | HK |
| — | WUXI BIOLOGICS (CAYMAN) INC. | 7.03% | Equity (common) | HK |
| — | Akeso Inc | 4.74% | Equity (common) | HK |
| — | Shenzhen Mindray Bio-Medical Electronics Co Ltd | 4.53% | Equity (common) | CN |
| — | CSPC PHARMACEUTICAL GROUP LIMITED | 4.35% | Equity (common) | HK |
| — | SINO BIOPHARMACEUTICAL LIMITED | 4.09% | Equity (common) | HK |
| — | HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 3.53% | Equity (common) | HK |
| — | WuXi AppTec Co., Ltd. | 3.23% | Equity (common) | CN |
| — | 3SBio Inc. | 2.90% | Equity (common) | HK |
| — | Shanghai United Imaging Healthcare Co., Ltd. | 2.25% | Equity (common) | CN |
| — | Aier Eye Hospital Group Co., Ltd. | 2.22% | Equity (common) | CN |
| — | YUNNAN BAIYAO GROUP CO., LTD | 2.17% | Equity (common) | CN |
| — | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 2.08% | Equity (common) | CN |
| — | SINOPHARM GROUP CO. LTD. | 1.67% | Equity (common) | HK |
| — | WuXi AppTec Co., Ltd. | 1.61% | Equity (common) | HK |
| — | HUADONG MEDICINE CO., LTD | 1.49% | Equity (common) | CN |
| — | WuXi XDC Cayman Inc | 1.44% | Equity (common) | HK |
| — | Sichuan Biokin Pharmaceutical Co Ltd | 1.26% | Equity (common) | CN |
| — | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 1.25% | Equity (common) | HK |
| — | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 1.17% | Equity (common) | CN |
| — | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 1.15% | Equity (common) | CN |
| — | XtalPi Holdings Ltd | 1.06% | Equity (common) | HK |
| — | Haisco Pharmaceutical Group Co., Ltd. | 1.05% | Equity (common) | CN |
| — | CSPC Innovation Pharmaceutical Co Ltd | 1.05% | Equity (common) | CN |
| — | Shanghai Pharmaceuticals Holding Co., Ltd. | 1.03% | Equity (common) | CN |
| — | Beijing Wantai Biological Pharmacy Enterprise Co Ltd | 1.02% | Equity (common) | CN |
| — | Shanghai Allist Pharmaceuticals Co Ltd | 1.02% | Equity (common) | CN |
| — | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 1.01% | Equity (common) | CN |
| — | Chongqing Zhifei Biological Products Co., Ltd. | 0.97% | Equity (common) | CN |
| — | Sichuan Kelun Pharmaceutical Co., Ltd. | 0.97% | Equity (common) | CN |
| — | Shenzhen New Industries Biomedical Engineering Co Ltd | 0.97% | Equity (common) | CN |
| — | BEIJING TONG REN TANG CO., LTD | 0.96% | Equity (common) | CN |
| — | Genscript Biotech Corp | 0.96% | Equity (common) | HK |
| — | Imeik Technology Development Co Ltd | 0.93% | Equity (common) | CN |
| — | Pharmaron Beijing Co., Ltd. | 0.91% | Equity (common) | CN |
| — | Shanghai RAAS Blood Products Co., Ltd. | 0.91% | Equity (common) | CN |
| — | RemeGen Co Ltd | 0.89% | Equity (common) | HK |
| — | CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. | 0.82% | Equity (common) | CN |
| LEGN | Legend Biotech Corp | 0.81% | Equity (common) | US |
| — | JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. | 0.80% | Equity (common) | CN |
| — | SHANDONG WEIGAO GROUP MEDICAL POLYMER CO.,LTD | 0.79% | Equity (common) | HK |
| — | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | 0.78% | Equity (common) | CN |
| — | APT Medical Inc | 0.76% | Equity (common) | CN |
| — | Beijing Tiantan Biological Products Corporation Limited | 0.70% | Equity (common) | CN |
| — | Hangzhou Tigermed Consulting Co., Ltd | 0.45% | Equity (common) | CN |
| — | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 0.11% | Equity (common) | CN |
| — | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 0.07% | Equity (common) | CN |
| — | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 0.05% | Equity (common) | CN |
Geographic Breakdown
Fund Holdings
KraneShares MSCI All China Health Care Index ETF ·
NPORT-P period 2026-03-31
(filed 2026-02-27)
Net assets:
$77M
· 58 total positions
· equity 99.93%
· non-equity -0.00%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | BEONE MEDICINES LTD-H COMMON STOCK | BeOne Medicines AG | 8.37% | $6.5M |
| 2 | JIANGSU HENGRUI PHARMACEUT-A COMMON STOCK | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 8.25% | $6.4M |
| 3 | INNOVENT BIOLOGICS INC COMMON STOCK | INNOVENT BIOLOGICS, INC. | 7.23% | $5.6M |
| 4 | WUXI BIOLOGICS CAYMAN INC COMMON STOCK | WUXI BIOLOGICS (CAYMAN) INC. | 7.03% | $5.4M |
| 5 | AKESO INC COMMON STOCK | Akeso Inc | 4.74% | $3.7M |
| 6 | SHENZHEN MINDRAY BIO-MEDIC-A COMMON STOCK | Shenzhen Mindray Bio-Medical Electronics Co Ltd | 4.53% | $3.5M |
| 7 | CSPC PHARMACEUTICAL GROUP LT COMMON STOCK | CSPC PHARMACEUTICAL GROUP LIMITED | 4.35% | $3.4M |
| 8 | SINO BIOPHARMACEUTICAL COMMON STOCK | SINO BIOPHARMACEUTICAL LIMITED | 4.09% | $3.2M |
| 9 | HANSOH PHARMACEUTICAL GROUP COMMON STOCK | HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 3.53% | $2.7M |
| 10 | WUXI APPTEC CO LTD-A COMMON STOCK | WuXi AppTec Co., Ltd. | 3.23% | $2.5M |
| 11 | 3SBIO INC COMMON STOCK | 3SBio Inc. | 2.90% | $2.2M |
| 12 | SHANGHAI UNITED IMAGING HE-A COMMON STOCK | Shanghai United Imaging Healthcare Co., Ltd. | 2.25% | $1.7M |
| 13 | AIER EYE HOSPITAL GROUP CO-A COMMON STOCK | Aier Eye Hospital Group Co., Ltd. | 2.22% | $1.7M |
| 14 | YUNNAN BAIYAO GROUP CO LTD-A COMMON STOCK | YUNNAN BAIYAO GROUP CO., LTD | 2.17% | $1.7M |
| 15 | ZHANGZHOU PIENTZEHUANG PHA-A COMMON STOCK | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 2.08% | $1.6M |
| 16 | SINOPHARM GROUP CO-H COMMON STOCK | SINOPHARM GROUP CO. LTD. | 1.67% | $1.3M |
| 17 | WUXI APPTEC CO LTD-H COMMON STOCK | WuXi AppTec Co., Ltd. | 1.61% | $1.2M |
| 18 | HUADONG MEDICINE CO LTD-A COMMON STOCK | HUADONG MEDICINE CO., LTD | 1.49% | $1.1M |
| 19 | WUXI XDC CAYMAN INC COMMON STOCK | WuXi XDC Cayman Inc | 1.44% | $1.1M |
| 20 | SICHUAN BIOKIN PHARMACEUTI-A COMMON STOCK | Sichuan Biokin Pharmaceutical Co Ltd | 1.26% | $973843 |
| 21 | SICHUAN KELUN-BIOTECH BIOP-H COMMON STOCK | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 1.25% | $962423 |
| 22 | SHENZHEN SALUBRIS PHARM-A COMMON STOCK | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 1.17% | $902732 |
| 23 | SHANGHAI FOSUN PHARMACEUTI-A COMMON STOCK | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 1.15% | $891213 |
| 24 | XTALPI HOLDINGS LTD COMMON STOCK | XtalPi Holdings Ltd | 1.06% | $816743 |
| 25 | HAISCO PHARMACEUTICAL GROU-A COMMON STOCK | Haisco Pharmaceutical Group Co., Ltd. | 1.05% | $813185 |
Showing top 25 of 53 equity holdings.
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -4.44% | 6 |
| Feb | +0.33% | 6 |
| Mar | -1.22% | 6 |
| Apr | -0.91% | 6 |
| May | +1.36% | 6 |
| Jun | +0.11% | 6 |
| Jul | +0.38% | 5 |
| Aug | -3.63% | 5 |
| Sep | +0.84% | 5 |
| Oct | -1.48% | 5 |
| Nov | +0.48% | 5 |
| Dec | -5.55% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $15.58
SMA 50: $16.75
SMA 200: $18.29
Current: $15.18
EMA 12: $15.22
EMA 26: $15.78
MACD: -0.5599 | Signal: -0.0273
BEARISH
ADX (14): 29.97
TREND
+DI: 21.12
−DI: 39.54
Momentum Oscillators
RSI (14): 39.04
NEUTRAL
Stoch %K: 29.79
Stoch %D: 18.62
Williams %R: -57.29
Volume & Volatility
BB Upper: $16.79
BB Lower: $14.37
NEUTRAL
OBV: 1,208,148
Vol SMA 20: 22,824
Vol ROC: -17.42%
ATR: $0.35
True Range: $0.31
HV 20: 27.3%
HV 30: 24.6%
HV 60: 26.2%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:17.527000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 39.58
- IV Rank (7D)
- 100
- Avg IV
- 65.7%
- Straddle (30D)
- $1.75
- Straddle (7D)
- $1.30
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.63
- Correlation (SPY)
- 28.9%
- R²
- 0.08
- Ann. Volatility
- 26.8%
- SPY Volatility
- 12.3%
Low volatility - stock moves less than market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|